Botanix Pharmaceuticals Ltd (ASX:BOT) has been granted a trading halt by the ASX this morning, pending details regarding ethics approval for its BTX 1503 acne patient study.
Botanix plans to progress into patient studies in coming months.
The company is targeting the multi-billion dollar market for acne treatments, where no new products have been approved in the last 20 years.
The halt will remain in place until the opening of trade on Monday 21st August 2017, or earlier if an announcement is made to the market.